[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100193231":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":27,"responsibleParty":38,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":26,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiolabeled 14C-canagliflozin","EXPERIMENTAL","Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.",[13],"Drug: Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)","A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.",[9],[21],"14C-JNJ-28431754",[23],{"name":24,"affiliation":5,"role":25},"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial","STUDY_DIRECTOR",null,[28],{"facility":26,"status":26,"city":29,"state":26,"zip":26,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":26},"Merksem","Belgium","BE",{"type":33,"coordinates":34},"Point",[35,36],4.44903,51.24623,{"lat":36,"lon":35},{"type":39,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100193231","phase-1-a-study-to-investigate-the-absorption-metabolism-and-excretion-of-canagliflozin-jnj-28431754-in-healthy-male-volunteers-100193231",false,"NCT01791231","A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers","An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-28431754 in Healthy Male Subjects Following a Single Oral Dose Administration of 14C-JNJ-28431754","Inclusion Criteria:\n\n* Body Mass Index (BMI) (weight \\[kg\\]\u002Fheight \\[m2\\]) between 18 and 30 kg\u002Fm2\n* Non-smoker\n\nExclusion Criteria:\n\n* Exposure to radiation for professional or medical reasons (except dental x-rays and x-rays of thorax and bone skeleton, excluding spinal column) in the past 12 months\n* History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results",true,"MALE","18 Years","45 Years",{"count":52,"type":53},6,"ACTUAL","INTERVENTIONAL",[56],"PHASE1","The purpose of this study is to investigate the absorption (the way the drug enters the body), metabolism (the way the drug is broken down in the body), and excretion (the way drug leaves the body) of canagliflozin (JNJ-28431754) in healthy male volunteers after a single dose of radiolabeled 14C-canagliflozin (14C-JNJ-28431754). The safety and tolerability of canagliflozin will also be assessed.",[59],"Healthy",[59,61,62,9,63,64,65,66],"Male","Canagliflozin (JNJ-28431754)","Absorption","Metabolism","Excretion","Radioactivity","COMPLETED","2016-06-28",{"date":70,"type":71},"2016-06-29","ESTIMATED",{"date":73,"type":26},"2007-08",{"date":75,"type":53},"2007-10",{"name":5,"class":6},1]